Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
HALO
HALO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HALO News
Halozyme Therapeutics Q1 Earnings Announcement Scheduled
2d ago
seekingalpha
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
1d ago
seekingalpha
Halozyme and GSK Reach Drug Delivery Technology Licensing Agreement
3d ago
seekingalpha
Halozyme Enters ENHANZE® Agreement with GSK for ADC Targets
4d ago
PRnewswire
HALOZYME AND GSK ENTER INTO GLOBAL PARTNERSHIP AND LICENSE DEAL TO ADVANCE SUBCUTANEOUS FORMULATIONS FOR SEVERAL PROMISING CANCER TARGETS
4d ago
moomoo
Halozyme to Release Q1 2026 Financial Results on May 11
Apr 30 2026
PRnewswire
Halozyme Appoints New CFO Darren Snellgrove
Apr 30 2026
NASDAQ.COM
Halozyme Appoints New Chief Financial Officer
Apr 30 2026
PRnewswire
Halozyme and Vertex Enter Exclusive Licensing Agreement
Apr 07 2026
seekingalpha
Halozyme Enters Exclusive Collaboration with Vertex Pharmaceuticals
Apr 07 2026
PRnewswire
Halozyme Appoints Interim CFO David Ramsay
Mar 12 2026
seekingalpha
Halozyme Appoints New Interim CFO David Ramsay
Mar 12 2026
PRnewswire
Halozyme Appoints New Interim CFO David Ramsay
Mar 12 2026
Newsfilter
Halozyme and Johnson & Johnson's Combination Therapy Approved
Mar 06 2026
NASDAQ.COM
FDA Approves Halozyme and Johnson & Johnson's TECVAYLI for Multiple Myeloma
Mar 06 2026
PRnewswire
FDA Approves Halozyme and Johnson & Johnson's TECVAYLI for Multiple Myeloma Treatment
Mar 06 2026
Newsfilter
Show More News
